patr-1 Antibody

What is PAR1 and why is it significant in research?

PAR1, also known as thrombin receptor, is a 65-70 kDa, 399 amino acid member of the seven-transmembrane G protein-coupled receptor superfamily. It is activated when thrombin cleaves its N-terminal propeptide in the extracellular domain, making it central to coagulation pathways. PAR1 is widely expressed in many cell types including endothelial cells and has been implicated in various inflammatory responses. The receptor's involvement in multiple physiological and pathological processes makes it a significant target for studying thrombosis, inflammation, and cellular signaling pathways .

How do human and mouse PAR1 antibodies differ in terms of cross-reactivity?

Human and mouse PAR1 proteins show significant sequence divergence, particularly in the extracellular domains. According to research data, human and mouse PAR1 proteins are only 58% identical in the region spanning the propeptide and extracellular domains, while sharing 84% identity in the cytoplasmic tail . This divergence means that antibodies developed against human PAR1 may not reliably cross-react with mouse PAR1, particularly if they target the extracellular region. Researchers must carefully validate cross-reactivity when translating between murine models and human samples, and should consider using species-specific antibodies for applications requiring high specificity.

What different formats of PAR1 antibodies are available for research applications?

Researchers can access several PAR1 antibody formats optimized for different experimental applications:

• Unconjugated primary antibodies for Western blotting and immunoprecipitation

• Fluorophore-conjugated antibodies (e.g., PE-conjugated) for flow cytometry and immunofluorescence

• Monoclonal antibodies for consistent results across experiments

• Polyclonal antibodies for increased sensitivity in certain applications

• Antibodies targeting different epitopes (N-terminal domain, extracellular loops, C-terminal domain)

What are the optimal conditions for using PAR1 antibodies in flow cytometry?

For optimal PAR1 detection by flow cytometry, researchers should consider:

• Sample preparation:

  • For platelets: Use freshly isolated peripheral blood platelets

  • For adherent cells: Employ gentle detachment methods that preserve surface epitopes

• Staining protocol:

  • Block with 1-5% BSA or serum before antibody incubation

  • Incubate with PE-conjugated PAR1 antibody, protected from light

  • Include appropriate isotype controls (e.g., Mouse IgG2B Phycoerythrin)

  • For platelets, co-stain with markers like CD41 to properly identify the population

• Instrument settings:

  • Optimize voltage settings using positive and negative controls

  • Collect sufficient events (≥10,000) for statistical significance

Research data demonstrates successful PAR1 detection in human peripheral blood platelets using PE-conjugated monoclonal antibodies, with clear discrimination from isotype controls .

How should PAR1 antibodies be prepared and stored to maintain optimal activity?

Proper storage and handling of PAR1 antibodies is crucial for maintaining their activity:

• Storage conditions:

  • Store most PAR1 antibodies at 2-8°C (refrigerated)

  • Never freeze PE-conjugated antibodies as this can damage the fluorophore

  • Always protect fluorophore-conjugated antibodies from light exposure

  • Typical shelf life is 12 months from receipt date when properly stored

• Working solution preparation:

  • Dilute in appropriate buffers containing protein stabilizers (0.5-1% BSA)

  • Prepare fresh working solutions when possible

  • Follow manufacturer-specific reconstitution instructions

The product information for PE-conjugated PAR1 antibodies specifically notes "Protect from light" and "Do not freeze" as critical storage requirements to maintain optimal performance .

What controls should be included when using PAR1 antibodies in research protocols?

Rigorous experimental design requires appropriate controls:

• Antibody controls:

  • Isotype controls matching the primary antibody's host species and conjugate

  • Positive control cells/tissues known to express PAR1 (e.g., platelets, HT-29 cells)

  • Negative control cells lacking PAR1 expression

• Technique-specific controls:

  • For flow cytometry: Fluorescence-minus-one (FMO) controls, unstained cells

  • For Western blotting: Loading controls, molecular weight markers

  • For immunofluorescence: Secondary-only controls

• Biological validation:

  • PAR1 knockdown/knockout cells where possible

  • Stimulation controls (e.g., thrombin-activated vs. resting cells)

Published research demonstrates the importance of isotype controls, showing specific PAR1 staining compared to mouse IgG-PE isotype control in both platelets and HT-29 human colon adenocarcinoma cells .

How can epitope binning improve PAR1 antibody selection for specific research applications?

Epitope binning provides critical insights for optimizing antibody selection:

• Mapping approach:

  • High-throughput surface plasmon resonance (SPR) can characterize antibody binding profiles

  • Competition assays identify antibodies binding to distinct epitopes

  • Comprehensive binning reveals subtle differences between seemingly similar antibodies

• Application-based selection:

  • For blocking experiments: antibodies targeting functional domains

  • For detection: antibodies recognizing accessible epitopes

  • For tracking receptor dynamics: antibodies that remain bound during conformational changes

• Practical implementation:

  • Competitive binding assays with natural ligands (e.g., thrombin)

  • Cross-competition studies between different antibody clones

  • Correlation of binding profile with functional outcomes

Similar approaches to those used for anti-PD-1 antibodies could identify PAR1 antibodies with optimal characteristics for specific applications. Research on anti-PD-1 antibodies revealed over ten unique competitive binding profiles through epitope binning, demonstrating the power of this approach .

What factors affect binding kinetics when using PAR1 antibodies in surface plasmon resonance (SPR)?

Understanding binding kinetics is crucial for optimizing experimental conditions:

• Surface chemistry effects:

  • Flat chip types (C1, CMD-P) versus 3D-hydrogel surfaces (CMD-200M)

  • Capture density of coupling antibodies

  • Coupling methods (direct vs. capture approaches)

• Experimental parameters:

  • Buffer composition (presence of BSA, detergents, salt concentration)

  • Flow rates and sample contact time

  • Analyte concentration ranges and purification quality

• Data analysis considerations:

  • Selection of appropriate binding models (1:1 Langmuir vs. more complex models)

  • Global vs. local fitting approaches

  • Reference surface subtraction methods

Research has shown that chip type significantly impacts measured kinetic parameters, with flat chip types yielding affinity constants that more closely match solution phase values compared to 3D-hydrogels. These findings emphasize the importance of consistent surface chemistry when comparing binding data across experiments .

How can researchers validate the specificity of PAR1 antibodies in their experimental systems?

Comprehensive antibody validation includes:

• Expression system validation:

  • Comparison of binding in cells with endogenous, overexpressed, and depleted PAR1

  • Correlation with mRNA expression data

  • Testing across multiple cell types with different PAR1 expression levels

• Multiple detection methods:

  • Verification across different techniques (flow cytometry, Western blot, immunofluorescence)

  • Confirmation of expected molecular weight and localization patterns

• Specificity controls:

  • Competition with soluble PAR1 protein or peptides

  • Comparison with related receptors (PAR2, PAR3, PAR4)

  • Testing on PAR1 knockout/knockdown systems

• Quantitative assessment:

  • Calculate signal-to-background ratios between positive and negative samples

  • Standard threshold for antibody specificity often requires >10-fold signal over background

Research on antibody validation suggests that high-quality antibodies should demonstrate substantial fold-increases over background (76-1260 fold reported for some well-characterized antibodies) when tested against cells expressing the target versus control cells .

How are PAR1 antibodies being utilized in inflammation research?

PAR1 plays important roles in inflammation that can be studied using antibodies:

• Endothelial function studies:

  • Investigation of PAR1-mediated endothelial barrier disruption

  • Analysis of leukocyte adhesion molecule upregulation

  • Assessment of cytokine/chemokine production

• Methodological approaches:

  • Blocking antibodies to assess PAR1 contribution to inflammatory signaling

  • Detection antibodies to monitor expression changes during inflammation

  • Co-localization studies with inflammatory mediators

• Translational relevance:

  • Expression analysis in inflammatory disease samples

  • Correlation with inflammatory biomarkers

  • Assessment of PAR1 as potential therapeutic target

Research has implicated PAR1 in various inflammatory responses, making it a valuable target for studying inflammation-related pathologies and potential therapeutic interventions .

What protocols exist for using PAR1 antibodies to study receptor internalization and trafficking?

Studying PAR1 dynamics requires specialized approaches:

• Immunofluorescence techniques:

  • Surface labeling with non-permeabilizing conditions

  • Time-course studies after thrombin stimulation

  • Co-localization with endosomal markers

• Flow cytometry approaches:

  • Surface vs. total receptor staining protocols

  • Antibody feeding assays to track internalized receptors

  • Quantification of receptor recovery after internalization

• Biochemical methods:

  • Cell surface biotinylation combined with immunoprecipitation

  • Subcellular fractionation with PAR1 immunodetection

  • Protease protection assays

• Live cell imaging:

  • PAR1 antibody fragments conjugated to pH-sensitive fluorophores

  • Pulse-chase experiments with differentially labeled antibodies

  • Total internal reflection fluorescence (TIRF) microscopy for membrane events

These techniques allow researchers to track the fate of PAR1 following activation, providing insights into receptor regulation mechanisms.

How can PAR1 antibodies be applied in cancer research?

PAR1 has emerging roles in cancer biology that can be studied using antibodies:

• Expression analysis:

  • Profiling PAR1 levels across cancer types and stages

  • Correlation with invasive/metastatic phenotypes

  • Single-cell analysis of heterogeneous tumor populations

• Functional studies:

  • Investigation of PAR1-mediated tumor cell migration and invasion

  • Analysis of matrix metalloproteinase activation

  • Assessment of PAR1's role in tumor-platelet interactions

• Technical approaches:

  • Immunohistochemistry on patient tissue microarrays

  • Multiplexed flow cytometry correlating PAR1 with cancer stem cell markers

  • In vivo imaging with PAR1-targeted antibodies

Research has demonstrated PAR1 expression in cancer cell lines like HT-29 human colon adenocarcinoma, indicating its relevance in cancer research contexts .

How should researchers interpret contradictory PAR1 antibody binding data?

Contradictory results require systematic investigation:

A comprehensive troubleshooting approach includes comparing multiple antibodies using standardized protocols, correlating with functional data, and validating with genetic approaches (knockout/knockdown/overexpression systems).

What quantitative methods exist for analyzing PAR1 expression levels across different cell types?

Quantitative assessment requires rigorous methodology:

• Flow cytometry quantification:

  • Antibody binding capacity (ABC) determination using calibration beads

  • Calculation of molecules of equivalent soluble fluorochrome (MESF)

  • Comparison of mean fluorescence intensity ratios between sample and isotype control

• Imaging-based quantification:

  • Digital image analysis with calibrated intensity standards

  • Ratio of membrane to cytoplasmic staining

  • Automated quantification of receptor clustering/distribution

• Protein-level quantification:

  • Quantitative Western blotting with recombinant standards

  • ELISA with purified reference material

  • Mass spectrometry using labeled peptide standards

• mRNA correlation:

  • qRT-PCR to compare transcript and protein levels

  • RNA-seq analysis for expression pattern identification

  • Single-cell approaches to assess heterogeneity

These approaches provide complementary data on both surface-accessible and total cellular PAR1 pools, enabling comprehensive expression profiling.

How are emerging technologies enhancing PAR1 antibody research capabilities?

Technological advances are expanding PAR1 research possibilities:

• High-throughput antibody characterization:

  • Array-based SPR systems can analyze hundreds of antibodies simultaneously

  • Microfluidic platforms for rapid epitope mapping

  • Deep sequencing of antibody repertoires for novel clone discovery

• Advanced imaging approaches:

  • Super-resolution microscopy to visualize receptor nanoclusters

  • Intravital imaging with PAR1-targeted probes

  • Correlative light-electron microscopy for ultrastructural localization

• Proteomics integration:

  • Antibody-based proximity labeling for PAR1 interactome mapping

  • Cross-linking mass spectrometry for structural insights

  • Targeted proteomics for precise PAR1 quantification

The development of instruments like the Carterra LSA enables high-throughput kinetic measurements and epitope binning studies that were previously impractical, allowing more comprehensive antibody characterization .

What considerations are important when selecting PAR1 antibodies for multiplexed assays?

Multiplexed detection requires careful planning:

• Antibody compatibility factors:

  • Species origin and isotype combinations

  • Fluorophore spectral overlap considerations

  • Buffer compatibility between antibodies

• Technical optimization:

  • Sequential vs. simultaneous staining protocols

  • Concentration titration for each antibody individually

  • Blocking strategy to minimize cross-reactivity

• Controls for multiplexed systems:

  • Single-stained controls for compensation

  • Fluorescence-minus-one (FMO) controls

  • Multi-color beads for instrument calibration

• Data analysis approaches:

  • Compensation matrices for spectral overlap

  • Dimensionality reduction techniques for complex datasets

  • Machine learning algorithms for pattern recognition

Proper antibody selection and validation are critical for generating reliable data in increasingly complex multiplexed assay systems.